Pacira BioSciences, Inc. — Director's Dealing 2011

Feb 2, 2011

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2011-02-02

Reporting Person: HBM BIOVENTURES CAYMAN LTD (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	92980	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Stock	$		Common Stock (1487680)		Direct
Common Stock Warrant s(Right to Buy)	$2.69	2014-01-21	Common Stock (37192)		Direct
Common Stock Warrants (Right to Buy)	$13.44	2017-12-29	Common Stock (41841)		Direct
Convertible Promissory Notes	$		Common Stock (1021223)		Direct

Footnotes

F1: The Series A convertible preferred s tock has no expiration date and will automatically convert into Common Stock upon the consummation of the Issuer's initial public offering.

F2: All principal and accrued interest due on these convertible promissory notes will automatically convert into shares of Common Stock upon the consummation of the Issuer's initial public offering at an effective conversion price of approximately $13.44 per share.